N,N'-bis-stearoyl-cystamine | 197389-42-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N,N'-bis-stearoyl-cystamine
• 英文别名: N-[2-[2-(octadecanoylamino)ethyldisulfanyl]ethyl]octadecanamide
• CAS: 197389-42-7
• 化学式: C₄₀H₈₀N₂O₂S₂
• 分子量: 685.219
• InChiKey: YUZKJBFBMPQSIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  16.4
• 重原子数：
  46
• 可旋转键数：
  39
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  cystamine dihydrochioride 、 硬脂酸 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N,N'-bis-stearoyl-cystamine
  参考文献：
  名称：

  A potential new prodrug for the treatment of cystinosis: Design, synthesis and in-vitro evaluation

  摘要：

  Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasant tasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attempt to improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathic cystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts. This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteamine bitartrate. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.039

文献信息

• Tissue reactive compounds and compositions and uses thereof
  申请人：Angiotech International AG

  公开号：US20040219214A1

  公开（公告）日：2004-11-04

  A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.

  一种组合物包括一种合成聚合物，可选地存在药物，并且该聚合物包括多个活性基团。这些多个活性基团与动物组织上存在的功能性反应，因此在将聚合物注射到组织中时，聚合物与组织结合。或者，这些多个活性基团与非生物表面上存在的功能性反应，聚合物将与该表面结合，例如增加表面的润滑性。当组合物中存在药物时，药物将被传递到聚合物附着的部位。
• TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF
  申请人：ANGIOTECH INTERNATIONAL AG

  公开号：EP1583561A3

  公开（公告）日：2005-12-07
• [EN] TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSES ET COMPOSITIONS REAGISSANT AVEC DES TISSUS ET UTILISATIONS ASSOCIEES
  申请人：ANGIOTECH INTERNAT GMBH

  公开号：WO2004060405A2

  公开（公告）日：2004-07-22

  A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functinality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.
• A potential new prodrug for the treatment of cystinosis: Design, synthesis and in-vitro evaluation
  作者：Bridgeen McCaughan、Graeme Kay、Rachel M. Knott、Donald Cairns

  DOI：10.1016/j.bmcl.2008.01.039

  日期：2008.3

  Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of most organs. The disorder is treated by regular administration of the aminothiol, cysteamine, an odiferous and unpleasant tasting compound that along with its metabolites is excreted in breath and sweat, leading to poor patient compliance. In an attempt to improve patient compliance a series of novel prodrugs has been designed and evaluated as a potential new treatment for nephropathic cystinosis. The first of the prodrugs tested, 3a, was found to decrease the levels of intracellular cystine in cystinotic fibroblasts. This is the first report of a potential new therapeutic treatment for nephropathic cystinosis since the advent of cysteamine bitartrate. (C) 2008 Elsevier Ltd. All rights reserved.